P-586 Phase II study of docetaxel and celecoxib as first or second linetherapy in patients with advanced NSCLC - Underhill, C.; Hui, R.; Links, M.; Hawson, G.; Chern, B.; Yip, D.; Blackwell, T.; Crombie, C.; Boyer, M. (Lung Cancer (01695002), 2005)